Immuron says Phase 2 Travelan trial results published in Scientific Reports
IMRN•Immuron said Phase 2 results for once-daily oral Travelan were published in Scientific Reports. The trial missed its primary efficacy targets after an unexpectedly low placebo illness rate reduced statistical power, while secondary measures favored Travelan.
1. Trial results
The Phase 2 trial missed its primary efficacy targets, which the company said was due to an unexpectedly low rate of illness in the placebo group that reduced statistical power. Secondary measures consistently favored Travelan, pointing to fewer and less severe diarrheal illnesses than with placebo.
2. Development plans
The trial showed a clean safety profile. Immuron has shifted development focus to a delayed-release, once-daily capsule intended for larger, adequately powered studies.
